

Proadrenomedullin and prognostic value for pneumonia

Dear Editor,

We read the publication on "Proadrenomedullin (proADM) determining clinical severity and analyzing prognostic value for pneumonia" with a great interest.^[1] Demirsoy *et al.* concluded that "Using proADM levels alone to predict pneumonia prognosis and mortality and deciding upon a therapy setting make no sense, although in consideration of previous studies, proADM would be useful as a supplementary contributor to clinical severity scores.^[1]" Indeed, the diagnostic value of proADM in pneumonia is interesting. Several reports, including to the present report, show that proADM might be useful. Nevertheless, there are many important considerations. First, proADM might be altered due to other medical underlying factors. The heart disease is another important medical problem that can result in alteration on proADM level.^[2] Furthermore, other underlying lung disease such as chronic obstructive lung disease can also result in alteration of proADM level.^[3]

Financial support and sponsorship
Nil.

Conflicts of interest

There are no conflicts of interest.

Beuy Joob, Viroj Wiwanitkit¹

Sanitation 1 Medical Academic Center, Bangkok Thailand, ¹Department of Community Medicine, Dr. DY Patil University, Pune, Maharashtra, India

ORCID:

Beuy Joob: <http://orcid.org/0000-0002-5281-0369>

Viroj Wiwanitkit: <http://orcid.org/0000-0003-1039-3728>


Address for correspondence:

Dr. Beuy Joob,
Sanitation 1 Medical Academic Center, Bangkok Thailand.
E-mail: beuyjoob@hotmail.com

References

1. Demirsoy S, Okutan O, Kartaloglu Z, Tas D, Ayten O, Canoglu K. Proadrenomedullin determining clinical severity and analyzing prognostic value for pneumonia. *Eurasian J Pulmonol* 2019;21:97-106.
2. Nishikimi T, Nakagawa Y. Adrenomedullin as a biomarker of heart failure. *Heart Fail Clin* 2018;14:49-55.
3. Schuetz P, Marlowe RJ, Mueller B. The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): A qualitative clinical review. *Clin Chem Lab Med* 2015;53:521-39.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online	
Quick Response Code:	Website: www.eurasianjpulmonol.com
	DOI: 10.4103/ejop.ejop_72_19

How to cite this article: Joob B, Wiwanitkit V. Proadrenomedullin and prognostic value for pneumonia. *Eurasian J Pulmonol* 2020;22:70.

Received: 30-08-2019

Revision: 10-10-2019

Accepted: 08-11-2019

Published: 30-04-2020

© 2020 Eurasian Journal of Pulmonology Published by Wolters Kluwer - Medknow